Cargando…
Effect of CYP3A4, CYP3A5, MDR1 and POR Genetic Polymorphisms in Immunosuppressive Treatment in Chilean Kidney Transplanted Patients
Cyclosporine (CsA) and tacrolimus (TAC) are immunosuppressant drugs characterized by a narrow therapeutic range and high pharmacokinetic variability. The effect of polymorphisms in genes related to the metabolism and transport of these drugs, namely CYP3A4, CYP3A5, MDR1 and POR genes, has been evalu...
Autores principales: | Contreras-Castillo, Stephania, Plaza, Anita, Stojanova, Jana, Navarro, Gustavo, Carmona, Rodolfo, Corvalán, Fernando, Cerpa, Leslie, Sandoval, Christopher, Muñoz, Daniel, Leiva, Marina, Castañeda, Luis E., Farias, Nayaret, Alvarez, Carolina, Llull, Gabriel, Mezzano, Sergio, Ardiles, Leopoldo, Varela, Nelson, Rodríguez, María S., Flores, Claudio, Cayún, Juan Pablo, Krall, Paola, Quiñones, Luis A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685429/ https://www.ncbi.nlm.nih.gov/pubmed/34938174 http://dx.doi.org/10.3389/fphar.2021.674117 |
Ejemplares similares
-
Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?
por: Roco, Ángela, et al.
Publicado: (2014) -
CYP3A5*3, CYP3A4*1B and MDR1 C3435T Genotype Distributions in Ecuadorians
por: Sinués, Blanca, et al.
Publicado: (2008) -
Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014) -
Biological interactions of CYP2C19 genotypes with CYP3A4*18, CYP3A5*3, and MDR1-3435 in living donor liver transplantation recipients
por: Chiu, King-Wah, et al.
Publicado: (2013) -
Evaluation of limited-sampling strategies to calculate AUC((0–24)) and the role of CYP3A5 in Chilean pediatric kidney recipients using extended-release tacrolimus
por: Galvez, Carla, et al.
Publicado: (2023)